A Phase 2 Study Of Lattice Radiotherapy For Dose-Escalated Palliation Of Bulky Tumors
Posted Date: Jun 3, 2024
- Investigator: Andrew Frankart
- Specialties: Breast Cancer, Cancer, Cervical Cancer, Colorectal Cancer, Gynecologic Oncology, Head and Neck Cancer, Lung Cancer, Lymphoma, Oncology, Ovarian Cancer, Prostate Cancer, Radiation Oncology, Thyroid Cancer
- Type of Study: Device
This will be a single-institution, single-arm Phase II trial with an anticipated total of 37 patients enrolled. Treatment will consist of 5 fractions of lattice radiation therapy delivered every other day. The primary endpoints will include the efficacy of lattice therapy as evaluated by ORR (CR or PR per RECIST criteria) at 60 days (2 months) post-treatment and safety. Toxicity will be evaluated at day 5 (+/- 2 days), day 15 (+/- 5 days), day 30 (+/- 5 days), and day 60 (+/- 7 days) post-completion of lattice therapy. This study will also include a translational analysis of the impact of lattice therapy on systemic immune responses.
Criteria:
Patients 18 Years Or Older With A Solid Tumor Malignancy With A Clinical Indication For Radiation; Measurable Disease; Target Lesion(S) Amenable To Lattice Therapy; Ecog Performance Status Of 2 Or Better; And Life Expectancy Greater Than 3 Months.
Keywords:
Radiation, Spatial Fractionation, Palliation
For More Information:
Andrew J. Frankart
NULL
frankaaj@mail.uc.edu